

**Amendments to the Claims:**


Please cancel current claims 1-4 without prejudice. Applicants hereby expressly reserve the right to prosecute claims to the canceled subject matter in future applications.

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claims 1-4 (canceled)


5. (currently amended) ~~Compounds according to claim 4, wherein:~~ Compounds of formula (4),



wherein:

- R<sup>1</sup> is cyclopentyl;
- R<sup>3</sup> is -(CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub> (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the heterocyclic moiety is optionally substituted by 1 to 5 R<sup>4</sup> groups;
- each R<sup>4</sup> is independently chosen from halo, C<sub>1</sub>-C<sub>10</sub> alkyl, and R<sup>6</sup>-O-, and each C<sub>1</sub>-C<sub>10</sub> alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C<sub>1</sub>-C<sub>10</sub> alkyl, and cyano; or
- when two adjacent R<sup>4</sup> groups are both C<sub>1</sub>-C<sub>10</sub> alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;
- R<sup>6</sup> is hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl;
- R<sup>8</sup> and R<sup>9</sup> are hydrogen;
- z is an integer from 1 to 5; and
- y is an integer from 0 to 5.
- R<sup>3</sup> is -(CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub> (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the heterocyclic moiety is optionally substituted by 1 to 5 R<sup>4</sup> groups; and
- R<sup>8</sup> and R<sup>9</sup> are hydrogen.

6. (original) Compounds according to claim 5, wherein:  
R<sup>3</sup> is -(CH<sub>2</sub>)<sub>t</sub>[(1,2,4]triazolo[1,5-a]pyrimidinyl), optionally substituted by 1 to 3 R<sup>4</sup> groups;  
t is an integer from 1-3; and  
y is an integer from 1 to 3.
7. (original) Compounds according to claim 6, wherein:  
R<sup>3</sup> is -(CH<sub>2</sub>)<sub>t</sub>[(1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by 1 to 3 R<sup>4</sup> groups;  
each R<sup>4</sup> is independently chosen from halo and C<sub>1</sub>-C<sub>10</sub> alkyl optionally substituted with cyano; or  
two adjacent R<sup>4</sup> groups are both C<sub>1</sub>-C<sub>10</sub> alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S;  
z is an integer from 2 to 3; and  
y is 2.
8. (original) Compounds according to claim 7, wherein:  
R<sup>3</sup> is -(CH<sub>2</sub>)<sub>t</sub>[(1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by 2 R<sup>4</sup> groups; and  
each R<sup>4</sup> is independently chosen from halo, -CH<sub>3</sub>, and -C(CH<sub>3</sub>)<sub>2</sub>CN.
9. (original) Compounds according to claim 7, wherein two adjacent R<sup>4</sup> groups are both C<sub>1</sub>-C<sub>10</sub> alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S.
10. (original) Compounds according to claim 9, wherein:  
R<sup>3</sup> is -(CH<sub>2</sub>)<sub>t</sub>[(1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by at least one substituent chosen from halo and methyl; and  
two adjacent R<sup>4</sup> groups, together with the atoms to which they are attached form a 5-membered ring, wherein in said ring one carbon atom is replaced by O.
11. (original) Compounds of formula (4b),



wherein:

$R^3$  is  $-(CH_2)([1,2,4]triazolo[1,5-a]pyrimidinyl)$ , substituted by at least one substituent chosen from halo and methyl;


Q is chosen from N, O, and S;

$R^{4a}$ ,  $R^{4b}$ , and  $R^{4c}$  are independently chosen from hydrogen, halo,  $C_1$ - $C_{10}$  alkyl, and  $R^6$ -O-;

and

$R^6$  is chosen from hydrogen and  $C_1$ - $C_{10}$  alkyl.

12. (original) Compounds of formula (5),




wherein:

$R^{4a}$ ,  $R^{4b}$ , and  $R^{4c}$  are independently chosen from halo and  $C_1$ - $C_{10}$  alkyl;

$R^{4d}$ ,  $R^{4e}$ , and  $R^{4f}$  are independently chosen from halo,  $R^6$ -O-, and  $C_1$ - $C_{10}$  alkyl, wherein said  $C_1$ - $C_{10}$  alkyl is optionally substituted with at least one substituent chosen from halo and cyano; and

$R^6$  is  $C_1$ - $C_{10}$  alkyl or hydrogen.

13. (original) Compounds of formula (6),




(6)

wherein R<sup>4</sup> is halo.

14. (original) Compounds according to claim 13, wherein R<sup>4</sup> is chosen from fluorine and chlorine.

15. (original) Compounds of formula (7),




(7)

wherein R<sup>4</sup> is halo.

16. (original) Compounds according to claim 15, wherein R<sup>4</sup> is chosen from fluorine and chlorine.


17. (original) Compounds of formula (8),



(8)

wherein R<sup>4</sup> is halo.

18. (original) Compounds according to claim 17, wherein R<sup>4</sup> is chosen from fluorine and chlorine.
19. (original) Compounds according to claim 6, wherein:
  - R<sup>3</sup> is -(CH<sub>2</sub>)<sub>z</sub>[(1,2,4]triazolo[1,5-a]pyrimidinyl), optionally substituted by 1 to 3 R<sup>4</sup> groups;
  - each R<sup>4</sup> is independently chosen from halo, C<sub>1</sub>-C<sub>10</sub> alkyl, and R<sup>6</sup>-O-, and each C<sub>1</sub>-C<sub>10</sub> alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C<sub>1</sub>-C<sub>10</sub> alkyl, and cyano;
  - z is an integer from 1 to 3; and
  - y is 2.
20. (original) Compounds according to claim 19, wherein:
  - R<sup>6</sup> is hydrogen or methyl; and
  - z is an integer from 2-3.
21. (original) Compounds of formula (9),



wherein:

R<sup>4a</sup> is halo or C<sub>1</sub>-C<sub>10</sub> alkyl;

R<sup>4b</sup>, R<sup>4c</sup>, and R<sup>4d</sup> are independently chosen from C<sub>1</sub>-C<sub>10</sub> alkyl and R<sup>6</sup>-O-; and  
R<sup>6</sup> is hydrogen or methyl.

22. (original) Compounds according to claim 21, wherein:

R<sup>4a</sup> is halo;

R<sup>4b</sup> and R<sup>4c</sup> are each R<sup>6</sup>-O-; and

R<sup>4d</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl.

23. (original) Compounds according to claim 22, wherein:

R<sup>4a</sup> is fluorine or chlorine;


R<sup>4b</sup> is -OCH<sub>3</sub>;

R<sup>4c</sup> is -OH; and


R<sup>4d</sup> is -CH<sub>2</sub>CH<sub>3</sub>.

24. (original) Compounds according to claim 23, wherein R<sup>4a</sup> is chlorine.

25. (original) A compound of formula (10),



26. (original) A compound of formula (11),



27. (currently amended) A compound chosen from:

- 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-fluoro-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
- 6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
- 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
- 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
- 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
- 6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-cyclopentyl-3-[(5,7-dimethyl [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione;  
7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl)methyl)-3-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;  
2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;  
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-5,6-dihydro-2H-pyran-2-one;  
6 N-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4,6-dioxotetrahydro-2H-pyran-2-yl}ethyl)-2-ethylphenyl]-N-methylmethanesulfonamide;  
2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1-methyl-1H-indol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;  
6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxyphenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
3-(5-Chloro-1-isopropyl-1-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
5-{6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-4-methyl-4H-[1,2,4]triazole-3-carboxylic acid methyl ester;  
3-(5-Chloro-1-methyl-1H-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-{[5-(2-furyl)-4-methyl-4H-1,2,4-triazol-3-yl]thio}-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one;  
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
8-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl}thio)-1,7-dihydro-6H-purin-6-one;



6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[[5-(4-hydroxyphenyl)-4*H*-1,2,4-triazol-3-yl]thio]-5,6-dihydro-2*H*-pyran-2-one;  
ethyl 2-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2*H*-pyran-3-yl}thio)[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxylate;  
6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
2-[4-(2-{5-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;  
2-[4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-tetrahydro-pyran-2-yl]-ethyl]-2-fluoro-phenyl]-2-methyl-propionitrile;  
2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
(+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
2-(4-[2-[5-(6-Chloro-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl]-2-fluoro-phenyl)-2-methyl-propionitrile;  
2-(4-[2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl]-2-fluoro-phenyl)-2-ethyl-butyronitrile;  
1-(4-[2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl]-2-fluoro-phenyl)-cyclopropanecarbonitrile;  
1-(4-[2-[5-(6-Chloro-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl]-2-fluoro-phenyl)-cyclopropanecarbonitrile;  
6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one;  
3-(6-Chloro-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-6-[2-(4-hydroxy-3-propylphenyl)ethyl]-5,6-dihydro-2*H*-pyran-2-one;  
6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

*N*-{2-[4-(2-[2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl)ethyl)-2-ethylphenoxy]ethyl}acetamide;  
2-(4-[2-[2-Cyclopentyl-5- 5,7-dimethyl- [1,2,4] triazolo[1,5-*a*]pyrimidin-2-ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;  
2-(4-[2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;  
2-(2-Chloro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-phenyl)-2-methyl-propionitrile;  
1-(2-Chloro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-phenyl)-cyclopropanecarbonitrile;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(+)-2-(2-chloro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-phenyl)-2-methyl-propionitrile;  
(-)-2-(2-chloro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-phenyl)-2-methyl-propionitrile;  
~~(+)-2-(2-fluoro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-phenyl)-2-methyl-propionitrile;~~  
(+)-2-(4-[2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-2-fluorophenyl)-2-methylpropionitrile;  
~~(-)-2-(2-fluoro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-phenyl)-2-methyl-propionitrile;~~  
(-)-2-(4-[2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl]-2-fluorophenyl)-2-methylpropionitrile;  
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;  
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-(2-hydroxy-ethoxy)-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and  
pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.

28. (currently amended)                      A compound chosen from:  
2-[4-(2-{5-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;  
2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
(+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;  
3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
*N*-[2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-ethylphenoxy]ethyl]acetamide;  
2-(4-{2-[2-Cyclopentyl-5- 5,7-dimethyl- [1,2,4] triazolo[1,5-a]pyrimidin-2-ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;  
(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;

(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;  
~~(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;~~  
(+)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile;  
~~(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;~~  
(-)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile;  
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-[3-ethyl-4-(2-hydroxy-ethoxy)-phenyl]-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and  
the pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.

29. (currently amended)                      A compound chosen from:

~~(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;~~  
~~(+)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile;~~  
~~(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;~~  
~~(-)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile;~~  
(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;  
(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;  
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;  
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and  
pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.

30. (currently amended) A method of treating Hepatitis C virus in a mammal, comprising administering to said mammal an amount of a compound according to ~~claim 4~~ claim 5 that is effective in treating HCV.

31. (currently amended) A method of inhibiting Hepatitis C virus polymerase, comprising contacting said polymerase with a polymerase-inhibiting amount of a compound according to ~~claim 4~~ claim 5.

32. (currently amended)            A pharmaceutical composition for the treatment of Hepatitis C virus in a mammal, comprising an amount of a compound according to ~~claim 4~~ claim 5 that is effective in treating Hepatitis C virus, and a pharmaceutically acceptable carrier.